Article Text

PDF
Letters
Pilot study of vapotherm oxygen delivery in moderately severe bronchiolitis
  1. Tom N Hilliard1,
  2. Neil Archer1,
  3. Hole Laura1,
  4. Jane Heraghty1,
  5. Hannah Cottis1,
  6. Katherine Mills1,
  7. Steve Ball2,
  8. Peter Davis3
  1. 1Department of Paediatric Respiratory Medicine, Bristol Children's Hospital, Bristol, UK
  2. 2Clinical Site Team, Bristol Children's Hospital, Bristol, UK
  3. 3Paediatric Intensive Care Unit, Bristol Children's Hospital, Bristol, UK
  1. Correspondence to Dr Tom Hilliard, Consultant Respiratory Paediatrician, Department of Paediatric Respiratory Medicine, Bristol Children's Hospital, Bristol BS2 8BJ, UK; tom.hilliard{at}uhbristol.nhs.uk

Statistics from Altmetric.com

Heated humidified high flow nasal cannula (HHHFNC) therapy is becoming increasingly used in preterm infants and there is evidence that it can provide some degree of respiratory support.1 2 We designed a prospective, randomised, open pilot study to assess the safety and feasibility of using HHHFNC therapy in infants with bronchiolitis.

We recruited infants with a clinical diagnosis of moderately severe bronchiolitis. Following parental informed consent, infants were randomised to head-box oxygen or the Vapotherm 2000i (Vapotherm Inc, Stevensville, Maryland, USA). Initial vapotherm flow was 4 l/min with 100% oxygen and was increased up to 8 l/min if tolerated. Oxygen concentration was adjusted in both groups to achieve target pulse …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.